An update on the toxicity of Aβ in Alzheimer’s disease
暂无分享,去创建一个
[1] Jürgen Götz,et al. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia , 2008, Proceedings of the National Academy of Sciences.
[2] M. Fändrich,et al. Oligomeric and fibrillar species of β-amyloid (Aβ42) both impair mitochondrial function in P301L tau transgenic mice , 2008, Journal of Molecular Medicine.
[3] J. Götz,et al. Divergent phosphorylation pattern of tau in P301L tau transgenic mice , 2008, The European journal of neuroscience.
[4] J. Götz,et al. Animal models of Alzheimer's disease and frontotemporal dementia , 2008, Nature Reviews Neuroscience.
[5] J. Götz,et al. Human but not rat amylin shares neurotoxic properties with Aβ42 in long‐term hippocampal and cortical cultures , 2008, FEBS letters.
[6] J. Götz,et al. Soluble Beta-Amyloid Leads to Mitochondrial Defects in Amyloid Precursor Protein and Tau Transgenic Mice , 2008, Neurodegenerative Diseases.
[7] R. Cappai,et al. Delineating the Mechanism of Alzheimer’s Disease Aβ Peptide Neurotoxicity , 2008, Neurochemical Research.
[8] C. Sachse,et al. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils , 2007, Proceedings of the National Academy of Sciences.
[9] M. Staufenbiel,et al. Induction of Tau Pathology by Intracerebral Infusion of Amyloid-β-Containing Brain Extract and by Amyloid-β Deposition in APP × Tau Transgenic Mice , 2007 .
[10] R. Araya,et al. Treatment and prevention of mental disorders in low-income and middle-income countries , 2007, The Lancet.
[11] A. Papassotiropoulos,et al. Aβ treatment and P301L tau expression in an Alzheimer's disease tissue culture model act synergistically to promote aberrant cell cycle re‐entry , 2007, The European journal of neuroscience.
[12] Chunyu Wang,et al. Aβ40 Protects Non-toxic Aβ42 Monomer from Aggregation , 2007 .
[13] L. Mucke,et al. Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.
[14] W. Klein,et al. Aβ Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine* , 2007, Journal of Biological Chemistry.
[15] R. Kayed,et al. Small Molecule Inhibitors of Aggregation Indicate That Amyloid β Oligomerization and Fibrillization Pathways Are Independent and Distinct* , 2007, Journal of Biological Chemistry.
[16] G. Belfort,et al. Surface plasmon resonance and nuclear magnetic resonance studies of ABAD-Abeta interaction. , 2007, Biochemistry.
[17] C. Masters,et al. Concentration dependent Cu2+ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-beta peptide. , 2007, Biochemistry.
[18] N. Cairns,et al. TDP‐43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations , 2007, Journal of neuropathology and experimental neurology.
[19] T. Lehtimäki,et al. Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degeneration , 2007, Acta Neuropathologica.
[20] Jürgen Götz,et al. A Decade of Tau Transgenic Animal Models and Beyond , 2007, Brain pathology.
[21] Jürgen Götz,et al. β‐Amyloid treatment of two complementary P301L tau‐expressing Alzheimer's disease models reveals similar deregulated cellular processes , 2006, Proteomics.
[22] Bruce L. Miller,et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.
[23] D. Galati,et al. Accumulation of Amyloid Precursor Protein in the Mitochondrial Import Channels of Human Alzheimer’s Disease Brain Is Associated with Mitochondrial Dysfunction , 2006, The Journal of Neuroscience.
[24] C. Duijn,et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21 , 2006, Nature.
[25] S. Melquist,et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17 , 2006, Nature.
[26] Angus C. Nairn,et al. Synaptic plasticity: one STEP at a time , 2006, Trends in Neurosciences.
[27] J. Götz,et al. Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease? , 2006, Journal of neurochemistry.
[28] E. Coulson,et al. Does the p75 neurotrophin receptor mediate Aβ‐induced toxicity in Alzheimer's disease? , 2006, Journal of neurochemistry.
[29] Amedeo Caflisch,et al. Interpreting the aggregation kinetics of amyloid peptides. , 2006, Journal of molecular biology.
[30] R. Kayed,et al. ERK1/2 Activation Mediates Aβ Oligomer-induced Neurotoxicity via Caspase-3 Activation and Tau Cleavage in Rat Organotypic Hippocampal Slice Cultures* , 2006, Journal of Biological Chemistry.
[31] R. Nitsch,et al. Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice , 2006, Genes, brain, and behavior.
[32] J. Quinn,et al. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. , 2006, Human molecular genetics.
[33] F. Chen,et al. Active immunization trial in Aβ42-injected P301L tau transgenic mice , 2006, Neurobiology of Disease.
[34] M. Gallagher,et al. A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.
[35] C. Masters,et al. Amyloid-β Peptide Disruption of Lipid Membranes and the Effect of Metal Ions , 2006 .
[36] L. Pennanen,et al. Different tau epitopes define Aβ42-mediated tau insolubility , 2005 .
[37] X. Chen,et al. Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease , 2005 .
[38] P. Keller,et al. Globular amyloid β‐peptide1−42 oligomer − a homogenous and stable neuropathological protein in Alzheimer's disease , 2005 .
[39] M. Rowan,et al. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. , 2005, Biochemical Society transactions.
[40] M. Fändrich,et al. The aggregation kinetics of Alzheimer's β‐amyloid peptide is controlled by stochastic nucleation , 2005, Protein science : a publication of the Protein Society.
[41] R. Ravid,et al. Proteomic and Functional Analyses Reveal a Mitochondrial Dysfunction in P301L Tau Transgenic Mice* , 2005, Journal of Biological Chemistry.
[42] J. Götz,et al. Functional Genomics meets neurodegenerative disorders Part I: Transcriptomic and proteomic technology , 2005, Progress in Neurobiology.
[43] Jürgen Götz,et al. Functional Genomics meets neurodegenerative disorders Part II: Application and data integration , 2005, Progress in Neurobiology.
[44] Ian Parker,et al. Calcium Dysregulation and Membrane Disruption as a Ubiquitous Neurotoxic Mechanism of Soluble Amyloid Oligomers*♦ , 2005, Journal of Biological Chemistry.
[45] W. K. Cullen,et al. Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo , 2005, Nature Medicine.
[46] C. Barrow,et al. Surface behavior and lipid interaction of Alzheimer beta-amyloid peptide 1-42: a membrane-disrupting peptide. , 2005, Biophysical journal.
[47] Xi Chen,et al. ABAD enhances Aβ‐induced cell stress via mitochondrial dysfunction , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[48] Jill A. White,et al. Differential effects of oligomeric and fibrillar amyloid-β1–42 on astrocyte-mediated inflammation , 2005, Neurobiology of Disease.
[49] C. Masters,et al. Copper-Dependent Inhibition of Human Cytochrome c Oxidase by a Dimeric Conformer of Amyloid-β1-42 , 2005, The Journal of Neuroscience.
[50] M. Duchen,et al. Calcium signals induced by amyloid beta peptide and their consequences in neurons and astrocytes in culture. , 2004, Biochimica et biophysica acta.
[51] P. Day,et al. Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative polymerase chain reaction. , 2004, Analytical biochemistry.
[52] C. Haass,et al. Amyloid β-induced Changes in Nitric Oxide Production and Mitochondrial Activity Lead to Apoptosis* , 2004, Journal of Biological Chemistry.
[53] J. Götz,et al. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models , 2004, International Journal of Developmental Neuroscience.
[54] Xi Chen,et al. RAGE potentiates Aβ‐induced perturbation of neuronal function in transgenic mice , 2004, The EMBO journal.
[55] T. Bayer,et al. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. , 2004, The American journal of pathology.
[56] Peter J. Lenting,et al. LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms , 2004, Neuron.
[57] Feng Chen,et al. Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals. , 2004, Current drug targets.
[58] J. Streffer,et al. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy , 2004, Molecular Psychiatry.
[59] E. Rogaev,et al. Role for glyoxalase I in Alzheimer's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[60] L. Mucke,et al. Fyn Kinase Modulates Synaptotoxicity, But Not Aberrant Sprouting, in Human Amyloid Precursor Protein Transgenic Mice , 2004, The Journal of Neuroscience.
[61] Xi Chen,et al. Materials and Methods Som Text Figs. S1 and S2 Table S1 References Abad Directly Links A to Mitochondrial Toxicity in Alzheimer's Disease , 2022 .
[62] R. Nitsch,et al. Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice , 2004, Neurobiology of Disease.
[63] R. Anwyl,et al. Block of Long-Term Potentiation by Naturally Secreted and Synthetic Amyloid β-Peptide in Hippocampal Slices Is Mediated via Activation of the Kinases c-Jun N-Terminal Kinase, Cyclin-Dependent Kinase 5, and p38 Mitogen-Activated Protein Kinase as well as Metabotropic Glutamate Receptor Type 5 , 2004, The Journal of Neuroscience.
[64] R. Nitsch,et al. β-Amyloid Induces Paired Helical Filament-like Tau Filaments in Tissue Culture* , 2003, Journal of Biological Chemistry.
[65] T. Arendt. Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the ‘Dr. Jekyll and Mr. Hyde concept’ of Alzheimer’s disease or the yin and yang of neuroplasticity , 2003, Progress in Neurobiology.
[66] R. Nitsch,et al. Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice. , 2003, The American journal of pathology.
[67] X. Roucou,et al. p75 Neurotrophin Receptor Protects Primary Cultures of Human Neurons against Extracellular Amyloid β Peptide Cytotoxicity , 2003, The Journal of Neuroscience.
[68] M. Lynch,et al. Activation of the c-Jun N-terminal Kinase Signaling Cascade Mediates the Effect of Amyloid-β on Long Term Potentiation and Cell Death in Hippocampus , 2003, Journal of Biological Chemistry.
[69] L. Murri,et al. Causative and susceptibility genes for Alzheimer’s disease: a review , 2003, Brain Research Bulletin.
[70] J. Regula,et al. Reconstitution of γ-secretase activity , 2003, Nature Cell Biology.
[71] M. Robin,et al. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells , 2003, The Journal of cell biology.
[72] G. Krafft,et al. In Vitro Characterization of Conditions for Amyloid-β Peptide Oligomerization and Fibrillogenesis* , 2003, The Journal of Biological Chemistry.
[73] D. Selkoe. Alzheimer's Disease Is a Synaptic Failure , 2002, Science.
[74] Jürgen Götz,et al. Glial cells under physiologic and pathologic conditions. , 2002, Archives of neurology.
[75] A. Delacourte,et al. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease , 2002, Neurology.
[76] G. Lynch,et al. Uptake and pathogenic effects of amyloid beta peptide 1–42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists , 2002, Neuroscience.
[77] M. Vitek,et al. Tau is essential to β-amyloid-induced neurotoxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[78] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[79] G. Perini,et al. Role of p75 Neurotrophin Receptor in the Neurotoxicity by β-amyloid Peptides and Synergistic Effect of Inflammatory Cytokines , 2002, The Journal of experimental medicine.
[80] R. Lal,et al. Amyloid β protein forms ion channels: implications for Alzheimer's disease pathophysiology , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[81] R. Nitsch,et al. Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. , 2001, The Journal of biological chemistry.
[82] J. Hardy,et al. Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.
[83] R. Nitsch,et al. Compartmentalized tau hyperphosphorylation and increased levels of kinases in transgenic mice , 2001, Neuroreport.
[84] Jürgen Götz,et al. Tau and transgenic animal models , 2001, Brain Research Reviews.
[85] R. Nitsch,et al. Oligodendroglial tau filament formation in transgenic mice expressing G272V tau , 2001, The European journal of neuroscience.
[86] C. Masters,et al. Sublethal Concentrations of Prion Peptide PrP106–126 or the Amyloid Beta Peptide of Alzheimer's Disease Activates Expression of Proapoptotic Markers in Primary Cortical Neurons , 2001, Neurobiology of Disease.
[87] D. Neary,et al. Distinct behavioural profiles in frontotemporal dementia and semantic dementia , 2001, Journal of neurology, neurosurgery, and psychiatry.
[88] R. Nitsch,et al. Tau Filament Formation in Transgenic Mice Expressing P301L Tau* , 2001, The Journal of Biological Chemistry.
[89] Ralph A. Nixon,et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.
[90] D. Holtzman,et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.
[91] Kang Hu,et al. High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.
[92] R. Lal,et al. Fresh and globular amyloid β protein (1–42) induces rapid cellular degeneration: evidence for AβP channel‐mediated cellular toxicity , 2000 .
[93] R. A. Crowther,et al. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein , 2000, Acta Neuropathologica.
[94] H. Geerts,et al. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. , 1999, The American journal of pathology.
[95] Bin Zhang,et al. Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform , 1999, Neuron.
[96] J. Treanor,et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.
[97] Dominic M. Walsh,et al. Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons , 1999, The Journal of Neuroscience.
[98] B. Sommer,et al. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. , 1999, The American journal of pathology.
[99] Carl W. Cotman,et al. β-Amyloid Induces Local Neurite Degeneration in Cultured Hippocampal Neurons: Evidence for Neuritic Apoptosis , 1998, Neurobiology of Disease.
[100] H. Band,et al. Tau interacts with src-family non-receptor tyrosine kinases. , 1998, Journal of cell science.
[101] Christian Hölscher,et al. Possible Causes of Alzheimer's Disease: Amyloid Fragments, Free Radicals, and Calcium Homeostasis , 1998, Neurobiology of Disease.
[102] A Klug,et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[103] Ronald C. Petersen,et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.
[104] G. Schellenberg,et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia , 1998, Annals of neurology.
[105] T. Morgan,et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[106] B. Sommer,et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[107] G. Jicha,et al. Alz‐50 and MC‐1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau , 1997, Journal of neuroscience research.
[108] S. Younkin,et al. Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.
[109] X. Chen,et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.
[110] E. Rojas,et al. Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity , 1995, Cellular and Molecular Neurobiology.
[111] H. Braak,et al. Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.
[112] M. Goedert,et al. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. , 1995, The EMBO journal.
[113] L. Mucke,et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.
[114] Carl W. Cotman,et al. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[115] E. Rojas,et al. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[116] Carl W. Cotman,et al. In vitro aging of ß-amyloid protein causes peptide aggregation and neurotoxicity , 1991, Brain Research.
[117] C. Cotman,et al. Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. , 1991, European journal of pharmacology.
[118] D. Kirschner,et al. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. , 1990, Science.
[119] J. Walker,et al. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[120] C. Masters,et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[121] G. Glenner,et al. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .
[122] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[123] N. Schonrock,et al. Is tau aggregation toxic or protective: a sensible question in the absence of sensitive methods? , 2008, Journal of Alzheimer's disease : JAD.
[124] R. Cappai,et al. Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity. , 2008, Neurochemical research.
[125] Chunyu Wang,et al. Abeta40 protects non-toxic Abeta42 monomer from aggregation. , 2007, Journal of molecular biology.
[126] M. Staufenbiel,et al. Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. , 2007, The American journal of pathology.
[127] M. Asunción Morán,et al. Ultrastructural localization of intraneuronal Abeta-peptide in Alzheimer disease brains. , 2007, Journal of Alzheimer's disease : JAD.
[128] C. Masters,et al. Amyloid-beta peptide disruption of lipid membranes and the effect of metal ions. , 2006, Journal of molecular biology.
[129] Michela Gallagher,et al. A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.
[130] P. Keller,et al. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. , 2005, Journal of neurochemistry.
[131] X. Chen,et al. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[132] W. K. Cullen,et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. , 2005, Nature medicine.
[133] D. Selkoe,et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.
[134] P. Greengard,et al. Regulation of NMDA receptor trafficking by amyloid-beta. , 2005, Nature neuroscience.
[135] J. Götz,et al. Different tau epitopes define Abeta42-mediated tau insolubility. , 2005, Biochemical and Biophysical Research Communications - BBRC.
[136] B. Penke,et al. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. , 2004, Journal of peptide science : an official publication of the European Peptide Society.
[137] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[138] R. Deane,et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. , 2004, Neuron.
[139] J. Regula,et al. Reconstitution of gamma-secretase activity. , 2003, Nature cell biology.
[140] J. Trojanowski,et al. Neurodegenerative tauopathies. , 2001, Annual review of neuroscience.
[141] D. Small,et al. Alzheimer's disease and Abeta toxicity: from top to bottom. , 2001, Nature reviews. Neuroscience.
[142] P. S. St George-Hyslop,et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. , 2000, Nature.
[143] H. Lin,et al. Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity. , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[144] P. Lansbury,et al. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. , 1997, Annual review of biochemistry.
[145] A. Schmidt,et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. , 1996, Nature.
[146] C. Cotman,et al. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. , 1991, Brain research.
[147] G. V. Van Hoesen,et al. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.
[148] G. Glenner,et al. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.
[149] N. Iwata,et al. Neuropsychiatric Disease and Treatment , 2022 .